Lung Cancer
Conditions
Interventions
Sponsors
Sichuan Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Subjects sign written informed consent and voluntarily participate in this study; 2. Subjects diagnosed as non-small cell lung cancer (NSCLC) by histology or cytology; 3. Negative EGFR mutation and ALK fusion gene status tested by histology or plasma; 4. At least 18 years of age; 5. Subjects have previously received first-line camrelizumab and platinum-containing chemotherapy; 6. According to the judgment of the investigator, subjects who can receive camrelizumab-based therapy.
Exclusion criteria
Exclusion criteria: 1. Subjects who are receiving other immune drugs or immunotherapy; 2. Subjects who are participating in other clinical studies; 3. Subjects with other malignancies; 4. During period of pregnancy or breastfeeding; 5. Not suitable for participation in the opinion of investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival time, OS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival, PFS;Objective response rate, ORR;Disease control rate, DCR;Duration of remission;safety; | — |
Countries
China
Contacts
Public ContactJin Zhou
Sichuan Cancer Hospital
Outcome results
None listed